FinTrust Capital Advisors’s NovoCure NVCR Stock Holding History

FinTrust Capital Advisors’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$230	Hold	15	–	–	﹤0.01%	1337
2024 Q2	$252	Hold	15	–	–	﹤0.01%	1332
2024 Q1	$230	Hold	15	–	–	﹤0.01%	1234
2023 Q4	$219	Hold	15	–	–	﹤0.01%	1215
2023 Q3	$237	Buy	+15	New	+$432	﹤0.01%	1194
2019 Q3	–	Sell	-524	Closed	-$33K	–	1081
2019 Q2	$33K	Hold	524	–	–	0.01%	497
2019 Q1	$25K	Buy	524 +146	+39%	+$7.03K	0.01%	539
2018 Q4	$13K	Buy	+378	New	+$13.8K	0.01%	701

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Nordwand Advisors Radnor, Pennsylvania $572M AUM 23.09% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

FinTrust Capital Advisors's NVCR Position: Q3 2024 in Review

FinTrust Capital Advisors held its NovoCure (NVCR) position steady in Q3 2024 at 15 shares worth $230. The position accounts for ﹤0.01% of the portfolio, ranked #1337.

FinTrust Capital Advisors first reported a position in NVCR in Q4 2018 and has held it in 8 quarters since. The position peaked at $33K in Q2 2019. 224 funds tracked by Wall St. Rank hold NVCR as of Q3 2024.

FinTrust Capital Advisors held 15 shares of NovoCure worth $230 as of Q3 2024.
FinTrust Capital Advisors left its NovoCure share count unchanged in Q3 2024.
NovoCure made up ﹤0.01% of FinTrust Capital Advisors's portfolio in Q3 2024, its #1337 holding.
FinTrust Capital Advisors first reported a position in NovoCure in Q4 2018 and has held it in 8 quarters since.
FinTrust Capital Advisors's NovoCure position peaked at $33K in Q2 2019.
224 funds tracked by Wall St. Rank held NovoCure as of Q3 2024.

Based on FinTrust Capital Advisors's 13F filing for Q3 2024, filed 11 Oct 2024.